Select a medication above to begin.
Xeloda
capecitabine
Black Box Warnings .
Warfarin Drug Interaction
monitor PT/INR frequently in pts receiving concomitant warfarin and adjust warfarin dose accordingly; incr. PT/INR, bleeding, and death reported in pts w/ and w/o liver metastases; events occurred several days to months after starting capecitabine and w/in 1mo after capecitabine D/C
Adult Dosing .
Dosage forms: TAB: 150 mg, 500 mg
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
stage III colon CA, adjuvant tx
- [monotherapy]
- Dose: 1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Max: 8 cycles; Info: give after meals; do not cut/crush/chew tab
- [combo w/ oxaliplatin-containing regimen]
- Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Max: 8 cycles; Info: give after meals; do not cut/crush/chew tab
rectal CA, locally advanced, perioperative tx
- [combo w/ XRT]
- Dose: 825 mg/m^2/dose PO bid; Info: give after meals; do not cut/crush/chew tab
- [chemo combo tx w/o XRT]
- Dose: 1250 mg/m^2/dose PO bid; Info: give after meals; do not cut/crush/chew tab
colorectal CA, unresectable or metastatic
- [monotherapy]
- Dose: 1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: give after meals; do not cut/crush/chew tab
- [combo w/ oxaliplatin]
- Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: give after meals; do not cut/crush/chew tab
breast CA, advanced or metastatic
- [monotherapy]
- Dose: 1000-1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for paclitaxel- and anthracycline-resistant dz; give after meals; do not cut/crush/chew tab
- [combo w/ docetaxel]
- Dose: 1000-1250 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for anthracycline-resistant dz; give after meals; do not cut/crush/chew tab
- [combo w/ lapatinib (off-label)]
- Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ HER2-positive dz who have received prior tx, incl. anthracycline, taxane, and trastuzumab; give after meals; do not cut/crush/chew tab
- [combo w/ neratinib (off-label)]
- Dose: 750 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ HER2-positive dz who have received 2 or more anti-HER2 based regimens; give after meals; do not cut/crush/chew tab
gastric CA
- [unresectable or metastatic dz]
- Dose: 625 mg/m^2/dose PO bid on days 1-21 of 21-day cycle for up to 8 cycles; Alt: 850-1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab
- [HER2-positive metastatic dz, first-line tx]
- Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ gastric or gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab
esophageal CA
- [unresectable or metastatic dz]
- Dose: 625 mg/m^2/dose PO bid on days 1-21 of 21-day cycle for up to 8 cycles; Alt: 850-1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab
- [HER2-positive metastatic dz, first-line tx]
- Dose: 1000 mg/m^2/dose PO bid on days 1-14 of 21-day cycle; Info: for pts w/ gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen; give after meals; do not cut/crush/chew tab
pancreatic CA, adjuvant tx
- [830 mg/m^2/dose PO bid on days 1-21 of 28-day cycle]
- Max: 6 cycles; Info: give w/ gemcitabine; give after meals; do not cut/crush/chew tab
renal dosing
- [adjust dose amount]
- CrCl 30-50: decr. usual dose by 25%; CrCl <30: decr. usual dose, amount not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment: not defined, caution advised
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to fluorouracil, severe
- dihydropyrimidine dehydrogenase (DPD) deficiency, complete
- pregnancy 1st trimester
- baseline ANC <1500
- baseline Plt <100,000
- avoid: breastfeeding during tx and x1wk after D/C
- caution: pregnancy 2nd trimester
- caution: pregnancy 3rd trimester
- caution: pts of childbearing potential
- caution: male pts of reproductive potential
- caution: elderly pts
- caution: dihydropyrimidine dehydrogenase (DPD) deficiency, partial
- caution: nephrotoxic agent use, concurrent
- caution: renal impairment
- caution: hepatic impairment
- caution: CAD
- caution: bone marrow depression
Drug Interactions .
Overview
capecitabine
pyrimidine analog
- cytidine deaminase substrate
- CYP2C9 inhibitor, weak
- cardiotoxic effects
- immunosuppressive oncologic agent
- myelosuppressive oncologic agent
- nephrotoxicity
Contraindicated
- adenovirus vaccine, live
- chikungunya vaccine, live
- cholera vaccine, live
- cidofovir
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- aldesleukin
- allopurinol
- amikacin
- amikacin inhaled
- bosentan
- bumetanide
- cedazuridine
- chloramphenicol
- cladribine oral
- clofarabine
- deferiprone
- dexrazoxane
- epirubicin
- fexinidazole
- foscarnet
- ganciclovir
- gentamicin
- idarubicin
- leucovorin
- levomefolate
- mannitol
- methadone
- methotrexate
- palifermin
- penicillamine
- pentamidine
- polymyxin B
- primaquine
- rabies vaccine
- radium Ra 223 dichloride
- ropeginterferon alfa-2b
- streptomycin
- streptozocin
- tenofovir disoproxil
- tobramycin
- tobramycin inhaled
- valganciclovir
Monitor/Modify Tx
- acyclovir
- adalimumab
- adefovir dipivoxil
- ado-trastuzumab emtansine
- albendazole
- alectinib
- alemtuzumab
- aliskiren
- alogliptin
- amiloride
- amphotericin
- anagrelide
- anthrax immune globulin
- anthrax vaccine
- anti-thymocyte globulin
- asciminib
- asenapine
- aspirin
- atidarsagene autotemcel
- auranofin
- avelumab
- axitinib
- azathioprine
- azilsartan medoxomil
- balsalazide
- baricitinib
- benazepril
- benznidazole
- betibeglogene autotemcel
- bevacizumab
- bezlotoxumab
- binimetinib
- bleomycin
- bortezomib
- bosutinib
- botulism immune globulin
- cabozantinib
- candesartan cilexetil
- captopril
- carboplatin
- carfilzomib
- celecoxib
- certolizumab pegol
- chikungunya vaccine
- chlorothiazide
- chlorthalidone
- cilostazol
- cisplatin
- clindamycin
- clozapine
- cobimetinib
- colchicine
- colistimethate
- COVID-19 vaccine
- creatine
- cyclophosphamide
- cyclosporine
- cytomegalovirus immune globulin
- dabrafenib
- dapsone
- daunorubicin
- deferasirox
- deferoxamine
- deuruxolitinib
- diclofenac
- diclofenac topical
- diflunisal
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- doxorubicin
- dronedarone
- ebola vaccine, live
- efbemalenograstim alfa
- eflapegrastim (G-CSF)
- elivaldogene autotemcel
- enalapril
- enalaprilat
- encorafenib
- entrectinib
- etanercept
- ethacrynic acid
- etodolac
- everolimus
- exagamglogene autotemcel
- exenatide
- fam-trastuzumab deruxtecan
- fenoprofen
- filgrastim (G-CSF)
- flucytosine
- fluorouracil
- fluphenazine
- flurbiprofen
- fluvastatin
- fosinopril
- fosphenytoin
- fostamatinib
- furosemide
- givinostat
- glimepiride
- golimumab
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydrochlorothiazide
- hydroxychloroquine
- hydroxyurea
- ibrutinib
- ibuprofen
- ibuprofen lysine
- ifosfamide
- iloperidone
- imatinib
- immune globulin
- indapamide
- indomethacin
- infliximab
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- iohexol
- iomeprol
- iopamidol
- irbesartan
- itraconazole
- Japanese encephalitis vaccine
- ketoprofen
- ketorolac
- lapatinib
- leflunomide
- lenvatinib
- lifileucel
- linagliptin
- linezolid
- liraglutide
- lisinopril
- lithium
- lonafarnib
- losartan
- lovotibeglogene autotemcel
- lumateperone
- lutetium Lu 177 vipivotide tetraxetan
- lymphocyte immune globulin, anti-thymocyte globulin
- magnesium citrate
- magnesium salicylate
- margetuximab
- mavacamten
- meclofenamate
- mefenamic acid
- meloxicam
- meningococcal vaccine
- mercaptopurine
- mesalamine
- mesalamine rectal
- metolazone
- mirdametinib
- mitomycin
- mitoxantrone
- mobocertinib
- moexipril
- mycophenolate mofetil
- mycophenolic acid
- nabumetone
- naproxen
- neomycin
- nusinersen
- olmesartan medoxomil
- olsalazine
- osimertinib
- oxaliplatin
- oxaprozin
- pamidronate
- paromomycin
- pazopanib
- pegfilgrastim (G-CSF)
- peginterferon alfa 2a
- peginterferon beta 1a
- pemetrexed
- pentostatin
- perindopril
- pertuzumab
- phenytoin
- pioglitazone
- piroxicam
- plazomicin
- pneumococcal vaccine
- poliovirus vaccine
- polyethylene glycol
- polyethylene glycol/electrolytes
- ponatinib
- proguanil
- propafenone
- pyrimethamine
- quinapril
- ramipril
- ramucirumab
- respiratory syncytial virus vaccine
- Rho(D) immune globulin
- ribavirin
- rifabutin
- ripretinib
- rituximab
- rosiglitazone
- ruxolitinib topical
- salsalate
- sargramostim (GM-CSF)
- sarilumab
- satralizumab
- saxagliptin
- selumetinib
- sirolimus
- sitagliptin
- smallpox/mpox vaccine, live
- sorafenib
- sparsentan
- spironolactone
- stiripentol
- succimer
- sulfasalazine
- sulfate bowel prep
- sulindac
- sunitinib
- tacrolimus
- telavancin
- telmisartan
- temsirolimus
- tenofovir alafenamide
- teplizumab
- teriflunomide
- thalidomide
- tick-borne encephalitis vaccine
- tiopronin
- tivozanib
- tocilizumab
- tofacitinib
- tolmetin
- torsemide
- trabectedin
- trametinib
- trandolapril
- trastuzumab
- triamterene
- trimethoprim
- typhoid vaccine
- upadacitinib
- vaccinia immune globulin
- valacyclovir
- valproic acid
- valsartan
- vancomycin
- vandetanib
- voclosporin
- warfarin
- zanidatamab
- zenocutuzumab
- zidovudine
- ziv-aflibercept
- zoledronic acid
- zonisamide
Caution Advised
- folic acid (vitamin B9)
Adverse Reactions .
Serious Reactions
- cardiotoxicity
- diarrhea, severe
- GI toxicity, severe
- enterocolitis, necrotizing
- GI hemorrhage
- dehydration
- nephrotoxicity
- renal failure
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- hand-foot syndrome
- neutropenia
- lymphopenia
- thrombocytopenia
- anemia
- sepsis
- hypersensitivity rxn
- hyperbilirubinemia
- hepatotoxicity
- toxic leukoencephalopathy
- angioedema
- cutaneous lupus erythematosus
- keratitis
Common Reactions
- hand-foot syndrome
- diarrhea
- nausea
- anemia
- stomatitis
- abdominal pain
- vomiting
- hyperbilirubinemia
- fatigue
- dermatitis
- constipation
- fever
- lymphopenia
- neutropenia
- anorexia
- headache
- dizziness
- edema
- ocular irritation
- asthenia
- lethargy
- alopecia
- dyspnea
- dyspepsia
- pain
- rash
- dysgeusia
- GI disorders
- peripheral neuropathy
- insomnia
- dehydration
- conjunctivitis
- arthralgia
- venous thrombosis
- cough
- skin discoloration
- thrombocytopenia
- epistaxis
- chest pain
- GI hemorrhage
- ileus
Safety/Monitoring .
Monitoring Parameters
pregnancy test at baseline; CBC w/ diff at baseline, then before each cycle; Cr at baseline, then as clinically indicated; LFTs; s/sx skin rxn; consider dihydropyrimidine dehydrogenase (DPYD) genotyping before tx start
Pregnancy/Lactation .
Pregnancy
Clinical Summary
avoid use in 1st trimester, weigh risk/benefit in 2nd and 3rd trimesters; no human data available; risk of teratogenicity and embryo-fetal toxicity in 1st trimester based on animal data at 0.2x recommended human dose and risk of fetal death at 0.6x recommended human dose; risk of fetal harm low in 2nd and 3rd trimesters based on limited human data w/ fluorouracil
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x6mo after D/C in pts of childbearing potential and during tx and x3mo after D/C in male pts
Lactation
Clinical Summary
avoid breastfeeding during tx and x1wk after D/C; no human data available to assess risk of infant harm, though possible drug excretion into milk based on drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: liver, tissues; CYP450: none; Info: prodrug converted to fluorouracil
Excretion: urine 95.5% (3% unchanged), feces 2.6%; Half-life: 45min
Subclass: Antimetabolites, Pyrimidine Analogs
Mechanism of Action
inhibits DNA and RNA synthesis
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.